Skip to main content
Helmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logo
DHODH inhibitor brequinar
New Research Findings, MCD,

Potentiating Cancer Vulnerability to Ferroptosis: Off-Targeting Effects of DHODH Inhibitors

A research team at Helmholtz Munich revealed a specific mechanism that is able to promote cell death in cancer cells by pharmacological targeting of a ferroptosis surveillance system. Ferroptosis is a form of regulated oxidative cell death and has…

read more
New Research Findings, MCD,

New Approach in Cancer Therapy With Innovative Mechanism-of-Action for Ferroptosis Induction

A team of researchers led by Dr. Marcus Conrad from Helmholtz Munich discovered a novel anti-cancer drug, called icFSP1, which sensitizes cancer cells to ferroptosis. Ferroptosis is characterized by the iron-dependent oxidative destruction of…

read more
FSP1 condensates in green induced by icFSP1 surrounding a blue nucleus
spliceosome assembly
Awards & Grants, STB,

Unleashing splicing to understand biology and eventually tackle ‘untreatable’ diseases

Cells use editing tools to skip or rearrange information stored in DNA. Thanks to a 10-million-euro ERC Synergy Grant co-financed by ERC and UKRI, researchers have launched a new project to study how this machinery can be controlled with molecular…

read more
Transfer, Molecular Targets and Therapeutics, Pioneer Campus,

Helmholtz Munich Establishes State-of-the-Art Cryo-Electron Microscopy Technology

Enabling Breakthroughs in High-Resolution Structural Analysis of Therapeutic Targets and their Visualization in the Native Cellular Context

read more
Aktin Filamente Cryo-ET (Cryo Elektron Tomographie)
HMGU_Icon_Molecular_Targets
Featured Publication, ZYTO,

B Cells Promote Liver Cancer With Dangerous Dual Strategy

Inflammatory fatty liver disease (NASH, nonalcoholic steatohepatitis) and the resulting liver cancer are driven by autoaggressive T cells. Scientists from the German Cancer Research Center (DKFZ), Helmholtz Munich and the Technical University Munich…

read more
Transfer, STB,

Targeted Antibody Therapy Against Brain Tumor Glioblastoma

Prof. Reinhard Zeidler about hope in the fight against glioblastoma, the most common and malignant form of brain tumor and how he accelerates the development of antibodies into application.

read more

Press Contact

COMS Communications & Strategic Relations

Ingolstädter Landstr. 1